XRAY · DENTSPLY SIRONA Inc. · Stock research

Current Thesis

The Q2 print flagged in the prior note as the binary landed on 2026-08-06, and the market faded it. Headline numbers cleared the bar — net sales $898M against a $889.81M consensus, adjusted EPS $0.52 against $0.35 — but $44M of tariff refunds contributed $0.17 of that EPS, sales fell 4.1% reported and 6.3% in constant currency, and management told the call that Q3 earnings would sit below Q2 once the refund is excluded. Press coverage put the 2026-08-06 session at a 4.32% decline to $13.19 from a $13.78 prior close (Investing.com, 2026-08-06); by 2026-08-14 the last close was $11.59, 21.0% under the $14.68 52-week high with RSI(14) at 38.0. The FY2026 frame is unchanged — $3.5–3.6B sales and $1.40–1.50 adjusted EPS reaffirmed — and the self-help programme is still running. What changed is that the event the summer advance was priced into has come and gone, and the re-rating leg reversed on the result. The narrative is dead — the narrative leg resolved at the 2026-08-06 print and the tape gave the move back within six sessions.

Bullish and bearish views on DENTSPLY SIRONA Inc.

The model's bull view on DENTSPLY SIRONA Inc. (XRAY), in brief: Second consecutive top-line beat. Q2 net sales $898M vs $889.81M consensus (2026-08-06), following Q1's $880M print (2026-05-05). Revenue has stopped missing even while it shrinks. Cash generation inflected. Q2 operating cash flow $99M vs $48M in Q2 2025 (2026-08-06 release)… The bear view: The beat was refund-assisted. A $44M tariff refund added $0.17 per share inside the $0.52 adjusted figure; on the 2026-08-06 call management called it "totally unrelated to the operations of the business" and excluded tariff effects from the FY EPS guide. Organic contraction… Both cases follow in full.

Bull Case

• Second consecutive top-line beat. Q2 net sales $898M vs $889.81M consensus (2026-08-06), following Q1's $880M print (2026-05-05). Revenue has stopped missing even while it shrinks.
• Cash generation inflected. Q2 operating cash flow $99M vs $48M in Q2 2025 (2026-08-06 release), against Q1 2026 free cash flow of negative $12M. The cash line moved before the revenue line.
• Sequential margin repair. Adjusted EBITDA margin 21.3% in Q2 vs 14.7% in Q1 2026; adjusted operating margin 15.8% in Q2 vs negative 3.1% in Q1. GAAP diluted EPS $0.18, back in the black.
• Buyback restarted. 1.3 million shares repurchased in Q2 — the first repurchase since Q3 2024 per the 2026-08-06 call — funded from tariff refund proceeds, at an average price management described as below $10.
• Guide reaffirmed, not trimmed. FY2026 sales $3.500–3.600B (vs $3.582B est.) and adjusted EPS $1.40–1.50 (vs $1.42 est.), confirmed 2026-08-06.
• Wellspect Healthcare +7.1% YoY in Q2 — the non-dental franchise is the one segment compounding, and it is not exposed to the dental dealer cycle.
• Two-way sell-side revisions post-print: Baird to $15 from $14 and BMO Capital to $13 from $12; Piper Sandler maintained Neutral and raised to $14 on 2026-07-29.

Bear Case

• The beat was refund-assisted. A $44M tariff refund added $0.17 per share inside the $0.52 adjusted figure; on the 2026-08-06 call management called it "totally unrelated to the operations of the business" and excluded tariff effects from the FY EPS guide.
• Organic contraction deepened. Constant-currency sales fell 6.3% in Q2 after Q1's roughly flat +0.1%. The direction of the underlying business worsened quarter over quarter.
• Orthodontic and Implant Solutions fell 13.2% YoY in Q2 — the highest-multiple growth franchise is shrinking fastest; Connected Technology Solutions and Essential Dental Solutions also declined.
• YoY margin still down. Adjusted operating margin 15.8% vs 18.2% a year earlier, with the refund sitting inside the quarter.
• Q3 pre-guided lower. Management flagged seasonal sequential revenue decline and earnings below Q2 ex-refund, with "more of the improvement weighted towards the fourth quarter" (2026-08-06 call). A back-loaded plan concentrates the risk in one print.
• Leverage unmoved. Net debt/EBITDA 3.2x at Q2, unchanged from Q1 2026, while cash is being routed to repurchases.
• The tape rejected the result. A revenue and EPS beat produced a down session and an eight-day drift to $11.59 — below the $13, $14 and $15 targets published around the print.

Setup & Price Structure

Reference close 2026-08-14: $11.59; 52-week high $14.68 (-21.0%); RSI(14) 38.0; three-month return +15.1%. The shape is a summer advance into a known event, a gap rejection at the print, and no reclaim since. Price sits at the top of the $11–12 shelf that has contained the downside since spring, inside the broader $11–15 band the stock has traded all year and far below the $40-plus highs of 2021–22. There is no moving-average reclaim to point at and RSI at 38 is weak rather than washed out, so the base is unproven at this level.

Positioning and crowding observables, stated as observables: no earnings date falls inside the next 30 days — the next print is estimated early November — so the event that concentrated attention in July and early August is gone. Sell-side dispersion is wide and two-way: post-print raises from Baird ($15) and BMO ($13) against reported target cuts from Barclays, Mizuho, Citi and Evercore ISI, with a Hold consensus straddling spot. The issuer itself was a buyer in Q2 (1.3 million shares) rather than a seller of stock into strength. No insider Form 4 activity surfaced in the 30-day window reviewed here. Retail-sentiment clustering around the name is not visible in the coverage feed; what coverage exists is earnings-recap, not thematic.

Catalyst Calendar (next 30 days)

• 2026-09-01 — Medline Sinclair begins distributing the Connected Technology Solutions portfolio across Canada (announced 2026-07-28). Low-impact and non-binary: the first measurable effect would appear in Q4 CTS revenue, not in any September datapoint.
• ~2026-11-04 (est.) — Q3 2026 earnings. Outside the window, named because it is the next binary. Q2 was reported 2026-08-06, Q1 on 2026-05-05. Management has already pre-guided Q3 below Q2 excluding the $0.17 refund, so the bar is the FY guide's back-half arithmetic, not the quarter itself.
• No confirmed conference appearance, regulatory decision or scheduled corporate event inside the 30-day window.

What Would Change Our Mind

The structure that matters is the $11–12 shelf defended since spring; the post-print fade has walked price to the top of it, so the shelf gets tested rather than admired. A weekly close below $11 would say the low-teens base failed and that the mid-May-to-August advance was a rally inside a multi-year downtrend. Secondary conditions that would confirm the same read without a price break: the Q3 print (~2026-11-04 est.) showing a constant-currency decline worse than Q2's -6.3%, or any trim to the $1.40–1.50 adjusted EPS guide reaffirmed on 2026-08-06.

On the other side, the case for re-engagement would need price to close a week back above $13.78 — the 2026-08-05 pre-print close, which is what the gap rejection took away — paired with a Q3 organic sales line that stops contracting and an operating margin that holds above the 15.8% Q2 level without a one-time refund inside it. Absent both, this is a cheap multiple with a shrinking top line and a plan whose proof point is a quarter away; standing aside until a base forms is the defensible read.

Correlation Notes

• Dental capex and consumables cycle: results read across to Envista (NVST), Align Technology (ALGN), Henry Schein (HSIC) and Patterson. Q2 weakness was company-attributed to dental end markets, with Ortho and Implant Solutions -13.2%.
• Wellspect Healthcare decouples part of the base. The continence-care unit grew 7.1% in Q2 and does not share the dental dealer-inventory cycle.
• Tariff policy is a direct P&L input, not a macro backdrop. A $44M refund landed in Q2 2026 and management excluded tariff effects from FY guidance, so further rulings can move reported EPS with no change in demand.
• FX flatters the reported line. Q2 was -4.1% reported vs -6.3% constant currency; a dollar reversal widens the reported decline.
• Rate sensitivity via the balance sheet: net debt/EBITDA of 3.2x makes refinancing costs a live variable alongside the deleveraging plan announced 2026-02-27.